Prince of Songkhla University Debuts CAR-T Cell Cancer Treatment
Prince of Songkhla University's Faculty of Medicine has unveiled a locally-developed CAR-T Cell cancer treatment with a 90 percent recovery rate, reducing costs from 20 million baht to 2 million baht per patient. The university is expanding
Songkhla: The Faculty of Medicine at Prince of Songkhla University (PSU) has unveiled its PSU CAR-T Cell cancer treatment technology, which has achieved a 90 percent recovery rate in patients. The university is rapidly constructing a manufacturing facility targeting production of over 100 patient treatments annually.
On August 4, 2026, Assoc. Prof. Dr. Nalinee Govitwanawong, Vice Dean of Administration at PSU's Faculty of Medicine, revealed progress in treating blood cancer patients. The faculty has introduced an innovative CAR-T Cell therapy to treat lymphoma, leukemia, and autoimmune diseases such as systemic lupus erythematosus (SLE), with treatment results showing nearly 90 percent of patients achieved full recovery.
Assoc. Prof. Dr. Chakrawadee Chulamani, Director of the Center of Excellence in Stem Cell Transplantation and Cell Therapy, stated that the faculty has researched and developed the PSU CAR-T Cell treatment innovation to reduce costs from importing foreign products priced at nearly 20 million baht to just 2 million baht per treatment.
"To sustain treatment system development, PSU's Faculty of Medicine has constructed a manufacturing facility for PSU CD19CAR-T Cell production to increase capacity from approximately 30 patients annually to over 100 patients per year, while establishing partnerships with the private sector and international networks to expand treatment and scale up globally," Assoc. Prof. Dr. Chakrawadee said.
Regarding private sector collaboration, the Faculty of Medicine has partnered with Bangkok Phuket Hospital Company Limited to sign a cooperation agreement for developing CAR-T Cell Therapy innovation, combining academic expertise, research capabilities, and medical services.
The collaboration aims to establish systematic, safe, and standardized patient care with advanced innovations including Precision Medicine and Advanced Therapy Medicinal Products (ATMPs), alongside comprehensive care systems encompassing patient selection, suitability assessment, treatment planning, safety monitoring, complication surveillance, and long-term outcome follow-up by multidisciplinary teams.
This partnership focuses on increasing access to advanced treatment for patients in the Andaman region, southern Thailand, and international patients, as part of establishing an international-standard advanced medical center based on safety standards, research excellence, and genuine patient benefit, Assoc. Prof. Dr. Chakrawadee stated.
